



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Triclabendazole (Standard)

Cat. No.:	HY-B0621R
CAS No.:	68786-66-3
Molecular Formula:	C ₁₄ H ₉ Cl ₃ N ₂ OS
Molecular Weight:	359.66
Target:	Parasite; Caspase; Bcl-2 Family; PARP; Pyroptosis
Pathway:	Anti-infection; Apoptosis; Cell Cycle/DNA Damage; Epigenetics; Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description

Triclabendazole (Standard) is the analytical standard of Triclabendazole. This product is intended for research and analytical applications. Triclabendazole is an orally active parasite inhibitor. Triclabendazole has anti-Leishmania activity and induces gasdermin E (GSDME)-dependent pyroptosis by caspase-3 activation. Triclabendazole can be used for the research of *fasciola hepatica*^{[1][2][3]}.

REFERENCES

- [1]. Yan L, et al. Triclabendazole induces pyroptosis by activating caspase-3 to cleave GSDME in breast cancer cells [J]. *Frontiers in Pharmacology*, 2021, 12: 670081.
- [2]. Devine C, et al. Potentiation of triclabendazole action in vivo against a triclabendazole-resistant isolate of *Fasciola hepatica* following its co-administration with the metabolic inhibitor, ketoconazole [J]. *Veterinary parasitology*, 2012, 184(1): 37-47.
- [3]. Borges B S, et al. In vitro anti-Leishmania activity of triclabendazole and its synergic effect with amphotericin B [J]. *Frontiers in Cellular and Infection Microbiology*, 2023, 12: 1044665.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA